NCT00327860 Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
| NCT ID | NCT00327860 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Condition | Chronic Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,300 participants |
| Start Date | 2003-10 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,300 participants in total. It began in 2003-10 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Minnesota) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
Eligibility Criteria
Inclusion Criteria: * Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4 * Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4 * Willingness and ability to provide informed consent and assent * For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled. Exclusion Criteria: * Solid organ (other than kidney), bone marrow or stem cell transplantation * Cancer diagnosis and receiving treatment or within 12 months post completion of treatment * Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab) * HIV infection with detectable viral load despite current antiretroviral therapy * Current pregnancy or pregnancy within past twelve months * Inability to complete major data collection procedures * Not fluent in English or Spanish * Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves) * Existing moderate to severe congenital structural heart disease * Genetic syndromes involving the central nervous system (e.g., Downs syndrome) * History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)\<40, significant impairment in adaptive function and/or inability to independently execute self-care skills) * For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited
Contact & Investigator
Susan Furth, MD, PhD
PRINCIPAL INVESTIGATOR
Children's Hospital of Philadelphia
Frequently Asked Questions
Who can join the NCT00327860 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 22 Years, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00327860 currently recruiting?
Yes, NCT00327860 is actively recruiting participants. Contact the research team at FurthS@email.chop.edu for enrollment information.
Where is the NCT00327860 trial being conducted?
This trial is being conducted at Kansas City, United States, Philadelphia, United States.
Who is sponsoring the NCT00327860 clinical trial?
NCT00327860 is sponsored by Johns Hopkins Bloomberg School of Public Health. The principal investigator is Susan Furth, MD, PhD at Children's Hospital of Philadelphia. The trial plans to enroll 1,300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.